Document is current
Any future updates will be listed below
-
Authors
Wu, Lihteh http://orcid.org/0000-0002-3387-7058
Bordon, Arnaldo F.
Charles, Martin
Rodríguez, Francisco J.
Lee, JinKyung
Machewitz, Tobias
Mueller, Margarete
del Carmen Gay, Gabriela
Fromow-Guerra, Jans
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03470103 at ClinicalTrials.govDocuments that mention this clinical trial
Intravitreal aflibercept for the treatment of patients with neovascular age-related macular degeneration in routine clinical practice in Latin America: the AQUILA study
https://doi.org/10.1186/s40942-022-00425-w
-
Funding
Funding for this research was provided by:
Bayer AG
- License Information
-
More Information
Article History
Received: 24 May 2022
Accepted: 5 October 2022
First Online: 18 October 2022
Declarations
:
: The AQUILA study was conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation guideline E6: Good Clinical Practice. The protocol and any amendments were reviewed and approved by each study site’s Independent Ethics Committee or Institutional Review Board before the start of the study.
: Not applicable.
: Lihteh Wu: speaker: Bayer and Quantel Medical. Arnaldo F. Bordon: speaker: Bayer, Allergan, and Novartis. Martin Charles: consultant: Alcon; speaker: Alcon, Bayer, and Novartis; research funds: Alcon. Francisco J. Rodríguez: consultant: Bayer, Novartis, and Roche; speaker: Bayer, Novartis, and Roche; research funds: Novartis. JinKyung Lee: employee of Bayer AG, Berlin, Germany. Tobias Machewitz: employee of Bayer AG, Berlin, Germany. Margarete Mueller: employee of Bayer AG, Berlin, Germany. Gabriela del Carmen Gay: employee of Bayer SA, Munro, Argentina. Jans Fromow-Guerra: consultant: Bayer and Novartis; speaker: Bayer, DORC, IOSA, and Novartis.
